Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

CBL antibody

CBL Reactivity: Human, Mouse, Rat WB, ELISA, IHC, FACS, ICC Host: Mouse Monoclonal 3B12 unconjugated
Catalog No. ABIN968993
  • Target See all CBL Antibodies
    CBL (Cas-Br-M (Murine) Ecotropic Retroviral Transforming Sequence (CBL))
    Reactivity
    • 170
    • 76
    • 64
    • 2
    • 2
    • 1
    • 1
    Human, Mouse, Rat
    Host
    • 151
    • 17
    • 3
    • 1
    Mouse
    Clonality
    • 142
    • 30
    Monoclonal
    Conjugate
    • 75
    • 9
    • 8
    • 8
    • 8
    • 8
    • 8
    • 8
    • 8
    • 6
    • 4
    • 4
    • 4
    • 4
    • 4
    • 2
    • 2
    • 2
    This CBL antibody is un-conjugated
    Application
    • 81
    • 52
    • 52
    • 48
    • 31
    • 25
    • 21
    • 15
    • 12
    • 9
    • 9
    • 3
    • 1
    • 1
    • 1
    Western Blotting (WB), ELISA, Immunohistochemistry (IHC), Flow Cytometry (FACS), Immunocytochemistry (ICC)
    Purification
    purified
    Immunogen
    Purified recombinant fragment of human C-CBL expressed in E. coli.
    Clone
    3B12
    Isotype
    IgG1
  • Application Notes
    ELISA: 1:10000, WB: 1:500 - 1:2000, IHC: 1:200 - 1:1000, ICC: 1:200 - 1:1000, FCM: 1:200 - 1:400
    Restrictions
    For Research Use only
  • Format
    Liquid
    Buffer
    Ascitic fluid containing 0.03 % sodium azide.
    Preservative
    Sodium azide
    Precaution of Use
    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Storage
    4 °C/-20 °C
    Storage Comment
    4°C, -20°C for long term storage
  • Sproul, Xu, Wilhelm, Gire, Greene: "Cbl negatively regulates JNK activation and cell death." in: Cell research, Vol. 19, Issue 8, pp. 950-61, (2009) (PubMed).

    Sanada, Suzuki, Shih, Otsu, Kato, Yamazaki, Tamura, Honda, Sakata-Yanagimoto, Kumano, Oda, Yamagata, Takita, Gotoh, Nakazaki, Kawamata, Onodera, Nobuyoshi, Hayashi, Harada, Kurokawa, Chiba, Mori et al.: "Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. ..." in: Nature, Vol. 460, Issue 7257, pp. 904-8, (2009) (PubMed).

    Loh, Sakai, Flotho, Kang, Fliegauf, Archambeault, Mullighan, Chen, Bergstraesser, Bueso-Ramos, Emanuel, Hasle, Issa, van den Heuvel-Eibrink, Locatelli, Stary, Trebo, Wlodarski, Zecca, Shannon et al.: "Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. ..." in: Blood, Vol. 114, Issue 9, pp. 1859-63, (2009) (PubMed).

  • Target
    CBL (Cas-Br-M (Murine) Ecotropic Retroviral Transforming Sequence (CBL))
    Alternative Name
    C-CBL (CBL Products)
    Background

    Description: The cbl oncogene was first identified as part of a transforming retrovirus which induces mouse pre-B and pro-B cell lymphomas. As an adaptor protein for receptor protein-tyrosine kinases, it positively regulates receptor protein-tyrosine kinase ubiquitination in a manner dependent upon its variant SH2 and RING finger domains. Ubiquitination of receptor protein-tyrosine kinases terminates signaling by marking active receptors for degradation.

    Aliases: CBL, CBL2, NSLL, C-CBL, RNF55

    Molecular Weight
    120 kDa
    Gene ID
    867
    HGNC
    867
    Pathways
    TCR Signaling, Interferon-gamma Pathway, EGFR Signaling Pathway, EGFR Downregulation, VEGFR1 Specific Signals
You are here:
Support